Patents by Inventor Steven Birken
Steven Birken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7229781Abstract: The present invention provides methods to quantitate the hLH? core fragment in a sample. The present invention now makes it possible to evaluate the metabolism of hLH in premenopausal, perimenopausal and postmenopausal women and to distinguish between normal and abnormal physiological states.Type: GrantFiled: May 31, 2002Date of Patent: June 12, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Patent number: 7198954Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: August 1, 2000Date of Patent: April 3, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20070026466Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: September 27, 2006Publication date: February 1, 2007Inventors: John O'Connor, Galina Kovalevskaya, Steven Birken
-
Patent number: 7034124Abstract: This invention provides an antibody which specifically binds to hLH?cf without cross-reacting with hLH, hLH? or hCG?cf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No. 12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLH?cf or hLH?cf-related molecule in a sample.Type: GrantFiled: September 23, 1999Date of Patent: April 25, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Steven Birken, John O'Connor, Galina Kovalevskaya
-
Patent number: 6927034Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: May 13, 1999Date of Patent: August 9, 2005Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20050042702Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: September 1, 2004Publication date: February 24, 2005Applicant: The Trustees of Columbia UniversityInventors: John Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20040058383Abstract: The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH&bgr;cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH&bgr;cf without substantially cross-reacting with hLH, hLH&bgr; or hLH&bgr;cf, under conditions permitting formation of a complex between the antibody and hLH&bgr;cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH&bgr;cf in the sample; and (c) comprising the amount of hLH&bgr;cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH&bgr;cf in the sample similar to the amount of hLH&bgr;cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause,Type: ApplicationFiled: February 10, 2003Publication date: March 25, 2004Inventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Publication number: 20030124737Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: December 31, 2002Publication date: July 3, 2003Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20030059842Abstract: The present invention provides methods to quantitate the hLH&bgr; core fragment in a sample. The present invention now makes it possible to evaluate the metabolism of hLH in premenopausal, perimenopausal and postmenopausal women and to distinguish between normal and abnormal physiological states.Type: ApplicationFiled: May 30, 2002Publication date: March 27, 2003Inventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Patent number: 6521416Abstract: The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH&bgr;cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH&bgr;cf without substantially cross-reacting with hLH, hLH&bgr; or hLH&bgr;cf, under conditions permitting formation of a complex between the antibody and hLH&bgr;cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH&bgr;cf in the sample; and (c) comprising the amount of hLH&bgr;cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH&bgr;cf in the sample similar to the amount of hLH&bgr;cf in the known postmenopausal sample indicates temporal proximity to the onset of menopaType: GrantFiled: August 1, 2000Date of Patent: February 18, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Publication number: 20030003597Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: May 13, 1999Publication date: January 2, 2003Inventors: JOHN O'CONNOR, STEVEN BIRKEN
-
Patent number: 6500627Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: February 3, 1998Date of Patent: December 31, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20020161198Abstract: This invention provides an antibody which specifically binds to hLH&bgr;cf without cross-reacting with hLH, hLH&bgr; or hCG&bgr;cf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No. 12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLH&bgr;cf or hLH&bgr;cf-related molecule in a sample.Type: ApplicationFiled: September 23, 1999Publication date: October 31, 2002Inventors: ROBERT E. CANFIELD, STEVEN BIRKEN, JOHN O'CONNOR, GALINA KOVALEVSKAYA
-
Patent number: 6339143Abstract: This invention provides methods for detecting the presence of human malignant cells in a sample of tumor cells; determining whether a tumor present in a human subject is malignant; obtaining an enriched population of live human malignant cells; determining the amount of intact luteinizing hormone in a sample; determining the ovulatory stage of a subject; determining the amount of intact follicle stimulating hormone in a sample; determining the ovulatory stage of a subject; determining the amount of intact human chorionic gonadotropin in a sample; determining whether a subject is pregnant; determining the ovulatory stage of a subject; determining the amount of free &agr; subunit of human luteinizing hormone in a sample; determining whether a subject has a malignant tumor; determining the amount of nicked human chorionic gonadotropin in a sample; and determining the likelihood of a fetus's being afflicted with Down's syndrome.Type: GrantFiled: June 7, 1995Date of Patent: January 15, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: Alexander Krichevsky, Steven Birken, John O'Connor, Robert E. Canfield
-
Patent number: 5976876Abstract: This invention provides an antibody which specifically binds to hLH.beta.cf without cross-reacting with hLH, hLH.beta. or hCG.beta.cf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No.12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLH.beta.cf or hLH.beta.cf-related molecule in a sample.Type: GrantFiled: December 11, 1996Date of Patent: November 2, 1999Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Steven Birken, John O'Connor, Galina Kovalevskaya
-
Patent number: 4851356Abstract: An immunoassay for detecting and measuring hCG in a sample includes an antibody directed to the carboxy terminal portion of the .beta. subunit of hCG and a monoclonal antibody directed to a determinant on hCG at a locus sufficiently remote from the carboxy terminal portion of the .beta. subunit of hCG that both antibodies can simultaneously bind to hCG, wherein at least one of the antibodies is delectable when both are bound to hCG.In a presently preferred embodiment, an immunoassay for hCG or hCB.beta. in urine includes a purified, labeled or detectable serum-derived antibody directed to the carboxy-terminal portion of the .beta. subunit of hCG and a matrix-bound monoclonal antibody directed to a locus on the .beta. subunit sufficiently remote from the carboxy-terminal portion that both antibodies can simultaneously bind to hCG or hCG.beta..Type: GrantFiled: July 14, 1987Date of Patent: July 25, 1989Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Elmo G. Armstrong, Paul H. Ehrlich, Steven Birken